Abstract
Background
A recent post-infectious rat model with Campylobacter jejuni 81-176 has replicated the events noted in humans with post-infectious irritable bowel syndrome (IBS). In this study, we test whether prophylactic treatment with the antibiotic rifaximin will prevent the development of long-term altered bowel function in this model.
Methods
Sprague–Dawley rats were divided into two groups. Both groups were gavaged with a 1 mL solution of 108 cfu/mL of C. jejuni. However, one group was also prophylactically gavaged with a solution of rifaximin 200 mg per day for 3 days (the day before gavage, the day of gavage, and the day after gavage with C. jejuni). Fresh stool was collected from rats daily until two consecutive stool cultures were negative for C. jejuni. The rats were then housed for 3 months. At the end of 3 months, fresh stool was collected on three consecutive days to determine stool % wet weight and stool consistency on a stool score.
Results
Rats that received rifaximin antibiotic prophylaxis had a greater rate of stool shedding of C. jejuni. However, the mean duration of colonization was shorter in the rifaximin-treated group (10.3 ± 7.1 days) compared to rats receiving no prophylaxis (12.6 ± 5.9 days) (P < 0.01). After 3 months, rats that did not receive rifaximin had a greater variability in stool % wet weight (P < 0.01). Furthermore, the average stool consistency over 3 days of measurement was closer to normal in the rifaximin-treated rats, with a consistency of 1.1 ± 0.3, compared to 1.5 ± 0.4 in rats receiving no prophylaxis (P < 0.00001).
Conclusions
Prophylactic treatment of rats with the antibiotic rifaximin in a new animal model of post-infectious IBS with C. jejuni mitigated the development of long-term altered stool form and function.
Similar content being viewed by others
References
McKendrick MW, Read NW. Irritable bowel syndrome—post salmonella infection. J Infect. 1994;29:1–3.
Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: Postal survey of patients. BMJ. 1997;314:779–782.
Gwee KA, Leong YL, Graham C, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut. 1999;44:400–406.
Parry SD, Stansfield R, Jelley D, et al. Is irritable bowel syndrome more common in patients presenting with bacterial gastroenteritis? A community-based, case–control study. Am J Gastroenterol. 2003;98:327–331.
Barber R, Blakey A. Prevalence of gastrointestinal symptoms after bacterial gastroenteritis. Study did not include a control group. BMJ. 1997;314:1903.
Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: A six year follow up study. Gut. 2002;51:410–413.
Okhuysen PC, Jiang ZD, Carlin L, et al. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol. 2004;99:1774–1778.
Mearin F, Pérez-Oliveras M, Perelló A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterol. 2005;129:98–104.
Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome—a meta-analysis. Am J Gastroenterol. 2006;101:1894–1899.
Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47:804–811.
Pimentel M, Chatterjee S, Chang C, et al. A new rat model links two contemporary theories in irritable bowel syndrome. Dig Dis Sci. 2008;53:982–989.
Cabada MM, White AC Jr. Travelers’ diarrhea: an update on susceptibility, prevention, and treatment. Curr Gastroenterol Rep. 2008;10:473–479.
Bercík P, Wang L, Verdú EF, et al. Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterology. 2004;127:179–187.
Soyturk M, Akpinar H, Gurler O, et al. Irritable bowel syndrome in persons who acquired trichinellosis. Am J Gastroenterol. 2007;102:1064–1069.
Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord. 2005;5:19–30.
Taylor DN, McKenzie R, Durbin A, et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis. 2006;42:1283–1288.
Acknowledgments
We would like to thank Salix Pharmaceuticals for their financial support of this study. Furthermore, we would like to thank the Beatrice & Samuel A. Seaver Foundation, as well as the Shoolman Foundation for their ongoing financial support of this and other related work. The Cedars-Sinai Medical Center has a licensing agreement with Salix Pharmaceuticals.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pimentel, M., Morales, W., Jee, SR. et al. Antibiotic Prophylaxis Prevents the Development of a Post-Infectious Phenotype in a New Rat Model of Post-Infectious IBS. Dig Dis Sci 56, 1962–1966 (2011). https://doi.org/10.1007/s10620-010-1548-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-010-1548-z